Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2016 | 12-2015 | 12-2014 | 12-2013 | 12-2012 | |
| Sales | 570,450 | 402,356 | 276,571 | 246,575 | 226,686 |
| Cost of Goods | 437,649 | 296,081 | 210,814 | 174,690 | 171,207 |
| Gross Profit | 132,801 | 106,275 | 65,757 | 71,885 | 55,479 |
| Operating Expenses | 152,209 | 92,707 | 60,847 | 52,400 | 54,983 |
| Operating Income | -18,759 | 13,649 | 5,724 | 20,175 | 703 |
| Interest Expense | 39,923 | 19,338 | 10,957 | 1,561 | 463 |
| Other Income | -1,277 | 2,220 | -235 | 1,089 | -121 |
| Pre-tax Income | -59,959 | -3,469 | -5,468 | 19,703 | 119 |
| Income Tax | 10,212 | -1,168 | -2,190 | 7,935 | 4,380 |
| Net Income Continuous | -70,171 | -2,301 | -3,278 | 11,768 | -4,261 |
| Net Income | $-70,171 | $-2,301 | $-3,278 | $11,768 | $-4,261 |
| EPS Basic Total Ops | -1.83 | -0.07 | -0.10 | 0.38 | -0.14 |
| EPS Basic Continuous Ops | -1.83 | -0.07 | -0.10 | 0.38 | -0.14 |
| EPS Diluted Total Ops | -1.83 | -0.07 | -0.10 | 0.37 | -0.14 |
| EPS Diluted Continuous Ops | -1.83 | -0.07 | -0.10 | 0.37 | -0.14 |
| EPS Diluted Before Non-Recurring Items | 0.75 | -0.07 | 0.63 | 0.70 | 0.25 |
| EBITDA(a) | $37,947 | $43,168 | $25,614 | $37,903 | $18,035 |